Institution
Lenox Hill Hospital
Healthcare•New York, New York, United States•
About: Lenox Hill Hospital is a healthcare organization based out in New York, New York, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 2569 authors who have published 3561 publications receiving 114326 citations.
Topics: Population, Medicine, Angioplasty, Stent, Arthroplasty
Papers published on a yearly basis
Papers
More filters
••
Harvard University1, University of Paris2, Imperial College London3, University of Missouri–Kansas City4, Mayo Clinic5, Duke University6, University of Vermont7, Case Western Reserve University8, Lenox Hill Hospital9, Stanford University10, Great Lakes Institute of Management11, Eastern Maine Medical Center12, Carolinas Healthcare System13, Boston University14
TL;DR: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding.
Abstract: 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P = 0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P = 0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment. Conclusions Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.)
1,587 citations
••
Scott & White Hospital1, Columbia University Medical Center2, Stanford University3, Cleveland Clinic4, St. Paul's Hospital5, Duke University6, Cedars-Sinai Medical Center7, Lenox Hill Hospital8, University of Pennsylvania9, Emory University10, MedStar Washington Hospital Center11, New York University12, Brigham and Women's Hospital13
TL;DR: The findings show that TAVR as an alternative to surgery for patients with high surgical risk results in similar clinical outcomes.
1,319 citations
••
Duke University1, University of British Columbia2, Albert Einstein College of Medicine3, University of Parma4, University of Wisconsin-Madison5, Lenox Hill Hospital6, Columbia University7, New Generation University College8, Medical College of Wisconsin9, Stanford University10, University of Missouri11, National Institutes of Health12, University of California, Los Angeles13, Université Paris-Saclay14, University Hospital Heidelberg15, Sichuan University16, Cleveland Clinic17, Radboud University Nijmegen18, university of lille19, Catholic University of the Sacred Heart20, Osaka University21
TL;DR: A multidisciplinary panel comprised principally of radiologists and pulmonologists from 10 countries with experience managing COVID-19 patients across a spectrum of healthcare environments evaluated the utility of imaging within three scenarios representing varying risk factors, community conditions, and resource constraints, resulting in five main and three additional recommendations intended to guide medical practitioners in the use of CXR and CT in the management of COIDs.
1,232 citations
••
Paris Diderot University1, Lenox Hill Hospital2, University of Cincinnati3, Boston Children's Hospital4, Medical College of Wisconsin5, University of California, San Francisco6, Columbia University7, Johns Hopkins University8, Université de Montréal9, University of British Columbia10, Cliniques Universitaires Saint-Luc11
TL;DR: The updated official ISSVA classification of vascular anomalies is presented, acknowledging that it will require modification as new scientific information becomes available.
Abstract: Vascular anomalies represent a spectrum of disorders from a simple "birthmark" to life- threatening entities. Incorrect nomenclature and misdiagnoses are commonly experienced by patients with these anomalies. Accurate diagnosis is crucial for appropriate evaluation and management, often requiring multidisciplinary specialists. Classification schemes provide a consistent terminology and serve as a guide for pathologists, clinicians, and researchers. One of the goals of the International Society for the Study of Vascular Anomalies (ISSVA) is to achieve a uniform classification. The last classification (1997) stratified vascular lesions into vascular malformations and proliferative vascular lesions (tumors). However, additional disease entities have since been identified that are complex and less easily classified by generic headings, such as capillary malformation, venous malformation, lymphatic malformation, etc. We hereby present the updated official ISSVA classification of vascular anomalies. The general biological scheme of the classification is retained. The section on tumors has been expanded and lists the main recognized vascular tumors, classified as benign, locally aggressive or borderline, and malignant. A list of well-defined diseases is included under each generic heading in the "Simple Vascular Malformations" section. A short definition is added for eponyms. Two new sections were created: one dealing with the malformations of individually named vessels (previously referred to as "truncular" malformations); the second groups lesions of uncertain or debated nature (tumor versus malformation). The known genetic defects underlying vascular anomalies are included in an appendix. This classification is meant to be a framework, acknowledging that it will require modification as new scientific information becomes available.
963 citations
••
McMaster University1, St. Michael's Hospital2, University of Toronto3, St James's University Hospital4, Harvard University5, Tufts Medical Center6, University of Bologna7, Magna Græcia University8, Sapienza University of Rome9, University of Barcelona10, Baylor College of Medicine11, French Institute of Health and Medical Research12, Royal Columbian Hospital13, University of British Columbia14, Hospital de Sant Pau15, Hofstra University16, Lenox Hill Hospital17
TL;DR: This document provides European Respiratory Society/American Thoracic Society and ERS/ATS evidence-based recommendations for the use of noninvasive ventilation in acute respiratory failure based on the most current literature.
Abstract: Noninvasive mechanical ventilation (NIV) is widely used in the acute care setting for acute respiratory failure (ARF) across a variety of aetiologies. This document provides European Respiratory Society/American Thoracic Society recommendations for the clinical application of NIV based on the most current literature. The guideline committee was composed of clinicians, methodologists and experts in the field of NIV. The committee developed recommendations based on the GRADE (Grading, Recommendation, Assessment, Development and Evaluation) methodology for each actionable question. The GRADE Evidence to Decision framework in the guideline development tool was used to generate recommendations. A number of topics were addressed using technical summaries without recommendations and these are discussed in the supplementary material. This guideline committee developed recommendations for 11 actionable questions in a PICO (population–intervention–comparison–outcome) format, all addressing the use of NIV for various aetiologies of ARF. The specific conditions where recommendations were made include exacerbation of chronic obstructive pulmonary disease, cardiogenic pulmonary oedema, de novo hypoxaemic respiratory failure, immunocompromised patients, chest trauma, palliation, post-operative care, weaning and post-extubation. This document summarises the current state of knowledge regarding the role of NIV in ARF. Evidence-based recommendations provide guidance to relevant stakeholders.
922 citations
Authors
Showing all 2596 results
Name | H-index | Papers | Citations |
---|---|---|---|
Martin B. Leon | 163 | 1400 | 129393 |
Richard B. Devereux | 144 | 962 | 116403 |
Roxana Mehran | 141 | 1378 | 99398 |
Kenneth Offit | 122 | 576 | 46548 |
Alexandra J. Lansky | 114 | 632 | 54445 |
Joshua J. Jacobs | 107 | 455 | 34463 |
George Dangas | 102 | 773 | 41137 |
Jeffrey W. Moses | 100 | 571 | 58868 |
Michael J. Pencina | 100 | 419 | 55000 |
Roberto M. Lang | 96 | 823 | 56638 |
Scott C. Weaver | 92 | 536 | 32230 |
Michael A. Mont | 86 | 1072 | 32026 |
Michael R. Jaff | 82 | 442 | 28891 |
Stephen J. Meltzer | 82 | 276 | 24789 |
Jack Wang | 79 | 211 | 18756 |